StemCell Therapy

A lot has been said about CBD pet products and their capacity to tame anxiety and other stressors that pets experience. Anecdotal evidence indicates that many pet owners are happy with the cannabis products theyve used on their pets, stating they put their pets at ease when theyre exposed to stressors like fireworks and separation anxiety. Pet owners feel a sense of comfort when using these products, since there are little to no side effects associated with them.

A cannabis symposium hosted by the American Veterinary Medical Association (AVMA)last month delved into the topic of veterinary cannabis, with different experts discussing its pros and cons.

We certainly recognize the potential opportunities that cannabis-derived compounds may offer and acknowledge the significant interest in these possibilities, said Randall Gnatt, a senior regulatory counsel in the Office of Surveillance and Compliance in the FDAs Center for Veterinary Medicine.

RELATED: The Relationship Between CBD And Owning Pets Is Deeper Than You Think

Were also aware that some companies are marketing products in ways that violate the federal Food, Drug, and Cosmetic Act and then may put the health and safety of people and animals at risk.

Waking up to this every morning would surely give you more will to live. Unsplash/jonathan daniels, CC BY-SA

While Gnatt made it clear that CBD is a promising compound for both humans and animals, he also expressed the FDAs concern regarding it, particularly in the way in which the cannabinoid has been advertised by dozens of companies. Other than the approved human prescription drug, we know little about the potential effects of sustained or cumulative long-term use of CBD, he said.

RELATED: Some CBD Pet Products Dont Actually Contain Any CBD

We dont know about coadministration with other medicines or risks to vulnerable human and animal populations. This doesnt mean that we know CBD is categorically unsafe under all circumstances, but given the gaps in our current knowledge and the known risks that have been identified, were not at a point where we can conclude that CBD products are safe for use.

CBD and cannabis remain largely unregulated. While significant steps have been made over the years to validate the medicinal claims of cannabis, much work needs to be done in order to get a full picture of the plant, especially if were giving it to animals who have no say on the matter and who might be better off visiting their veterinarian.

See the original post:
What Pet Owners Should Know About Cannabis And CBD Products - The Fresh Toast

Global Veterinary Medicine Marketexpected to reach around US$ XX Bn by 2027, growing at a CAGR of 6.4% during the forecast period.

The MMR report includes various segments as well as an analysis of the trends and growth factors that are playing a substantial role in the market. These factors the market dynamics involve the drivers, restraints, opportunities, and challenges. Such as, The rise in the occurrence of contagious diseases among animals is driving the market for veterinary drugs. Animals also play a crucial role in research and development in studying drug therapy by performing preclinical trials in animals to develop advance drug and cost-effective veterinary drugs. Moreover, increasing awareness towards livestock and to cure zoonotic and chronic disease drives the market, rapid urbanization and an increase in per capita income drive the market growth.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/54077

However, the discovery of complex diseases and various infections in humans from animals through the consumption of animal products such as bird flu, bird flu, rabies, coronova virus, and others and not giving street animals appropriately treatment restraints the market growth.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Opportunities:

Growing research and development investment to develop more effective drugs Rising meat consumption across the globe and animal-derived product like ghee, milk, butter give a better opportunity.

Global Veterinary Medicine Market: Market Segmentation:

The report covers the brief analytical segments of the veterinary medicine market thereby providing a wider view at the macro as well as micro levels. By route of administration, parenteral is dominating the veterinary medicine market and valued around US$ XX Bn in 2019. Parenteral administration is more preferred over other as it gives rapid onset of action, The better bioavailability, and reliable dosage and it gives fast therapeutic effect with rapid onset of action as it overcomes the first-pass metabolism whereas, several adverse reactions and painful delivery and discomfort are the drawbacks and hinder the growth.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/54077

Pharmacies & drug stores segment is projected to witness the fastest growth during the forecast period. Because of the requirement and urgency in clinical for targeted medicines and to protect from zoonotic diseases and livestock animals.

Global Veterinary medicine market: Regional analysis

North Americas Veterinary medicine market was valued at US$ XX million in 2019 and is expected to reach a value of US$ XX million by 2027, with a CAGR of XX%. The major factors which are driving the growth of the Veterinary medicine market in the regions as it provides good animal welfare policies and its spend huge expenditure on research in veterinary medicine market especially the U.S and Canada. Since, North America is the developed region it consists of advance veterinary hospital and the large healthcare players and hence, take part in growing the economics of the market.

Europe is considered the second most promising market after North America in the Advancement of new techniques and growing healthcare agencies the European market is undertaken by Germany and Frances and so, drives the European market.

Recent Development:

In June 2018, Merck entered into a business with Vinovo B.V a division of Viscon Hatchery Automation. This has aided the company increase its portfolio of poultry vaccines.

The objective of the report is to present a comprehensive analysis of the Global Veterinary Medicine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Veterinary Medicine Market dynamics, structure by analyzing the market segments and project the Global Veterinary Medicine Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Veterinary Medicine Market make the report investors guide.Scope of the Global Veterinary Medicine Market:

Global Veterinary Medicine Market, By Product

DrugsAnti-infectivesAnti-inflammatoryParasiticides VaccinesInactivated VaccinesAttenuated VaccinesRecombinant Vaccines Medicated Feed AdditivesAmino acidsAntibioticsGlobal Veterinary Medicine Market, By Route of Administration

Oral Parenteral TopicalGlobal Veterinary Medicine Market, By Application

Companion Animals Livestock AnimalsGlobal Veterinary Medicine Market, By End-User

Veterinary Hospital Veterinary Clinics Pharmacies & Drug StoresGlobal Veterinary Medicine Market, By Region

North America Europe Asia Pacific Middle East and Africa Latin AmericaGlobal Veterinary Medicine Market, key Players

Agrovet Market Animal Health American Veterinary Clinic Animalcare BASF India Ltd Belfarmacom Bimeda Biotex Plus Ltd Boehringer Ingelheim Gmbh Brouwer Cadila Pharmaceuticals Ltd Cargill India Pvt. Ltd Ceva Chemo Argentina Koninklijke DSM N.V Mars Merck & Co. Saudi Pharmaceutical Industries Sauvet Selecta Syntec The British Veterinary Center UCBVET Vetanco Veterinarski Zavod Subotica Vetmedica Wageningen Bioveterinary Research Wilbur-Ellis Zoetis

MAJOR TOC OF THE REPORT

Chapter One: Veterinary Medicine Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Veterinary Medicine Market Competition, by Players

Chapter Four: Global Veterinary Medicine Market Size by Regions

Chapter Five: North America Veterinary Medicine Revenue by Countries

Chapter Six: Europe Veterinary Medicine Revenue by Countries

Chapter Seven: Asia-Pacific Veterinary Medicine Revenue by Countries

Chapter Eight: South America Veterinary Medicine Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Veterinary Medicine by Countries

Chapter Ten: Global Veterinary Medicine Market Segment by Type

Chapter Eleven: Global Veterinary Medicine Market Segment by Application

Chapter Twelve: Global Veterinary Medicine Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Veterinary Medicine Market Report at:https://www.maximizemarketresearch.com/market-report/global-veterinary-medicine-market/54077/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email:sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

See the original post here:
Global Veterinary Medicine Market- Industry Analysis and Forecast (2020-2027) by Product, Route of Administration, Application, End-User and Region....

Gucci, one of 4,000+ pet heroes treated at a PetCure Oncology cancer care center

West Islip, NY, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Advanced radiation therapy for pets with cancer will soon be available in Long Island, New York following the announcement of a new collaboration between PetCure Oncology and the Veterinary Medical Center of Long Island (VMCLI) on Tuesday.

The new service is already accepting referrals from local veterinarians with an opening date less than two weeks away on October 5. Those interested in more information or the advice of a board-certified veterinary radiation oncologist can call 833-PET-HERO, a toll-free number dedicated to supporting pets with cancer and the families who love them.

Located in central Long Island in West Islip, VMCLI is the islands leading veterinary specialty practice and 24/7 emergency center. The addition of radiation oncology, combined with VMCLIs current oncology offerings, provides pet owners in Long Island with access to comprehensive cancer care all under one roof at VMCLI - a first for the island.

We are really proud to bring this level of cancer care to pets in Long Island, said Dr. Robert Composto, DVM, Co-Founder and Director of VMCLI. We are committed to both learning and providing cutting-edge veterinary medicine. Adding radiation oncology and partnering with PetCure keeps VMCLI at the forefront of cancer treatment for pets.

The program will be overseen by Dr. Rick Chetney, a New York native and one of nine board-certified radiation oncologists in the PetCure Oncology national network.

PetCure Oncology is a national brand that develops and manages radiation therapy centers featuring stereotactic radiation (SRS/SRT), the most advanced form of radiation therapy available. Already a proven care option for human cancer patients, SRS/SRT has become increasingly common in the treatment of pets with cancer. PetCure Oncology has supported this process by increasing access to SRS/SRT for pet owners, facilitating innovative clinical trials, and sharing data and research results from over 4,000 treatments to improve the impact of this therapy on survival times and quality of life.

At the most recent meeting of the Veterinary Cancer Society, PetCure Chief Medical Officer Dr. Neal Mauldin presented preliminary outcomes data that suggested SRS/SRT delivered with PetCure-developed treatment protocols is leading to better survival outcomes than other treatment options for at least nine specific tumor types. The list includes some of the most common types of pet cancer, most notably brain tumors, nasal tumors, osteosarcoma, mast cell tumors and melanoma.

Its great news that so many of our pets are still alive and thriving, so the data is still maturing, explained Dr. Mauldin, whose board certifications include radiation oncology, medical oncology and internal medicine. But objective analysis of the preliminary data at this point suggests that stereotactic radiation can be considered a standard of care for the treatment of many tumor types - much like it already is in human cancer treatment.

About PetCure Oncology: PetCure Oncology LLC is a marketing and management services company affiliated with PetCure Radiation Oncology Specialists (PROS), a veterinary healthcare provider with nine board-certified radiation oncologists that have treated more than 4,000 pets with cancer since 2015. Supporting eight treatment centers across the country and counting, PetCure also facilitates innovative telehealth services for both veterinarians and pet owners. For more information, contact a PetCure Pet Advocate at 833-PET-HERO.

Follow this link:
PetCure Oncology and VMCLI Fighting Pet Cancer in Long Island, NY - GlobeNewswire

Friday, September 18, 2020

Did you know that Drew Brees is a professor at the College of Veterinary Medicine? A pet professor that is, or rather pet professors.

The legendary football player is represented in the college in the form of two dogs, a Terrier mix named Drew and an Australian Shepherd border mix named Brees. Brees is owned by Dr. Ellen Lowery, director of the Purdue University Veterinary Hospital, while Drew is owned by Dr. Jim Weisman, assistant dean for student affairs.

As far as the name Drew goes, its basically my admiration for Drew Brees. Im a Boilermaker through and through, Dr. Weisman says. Drew is about nine-years-old and Dr. Weisman describes him as a very self-sustained dog. He enjoys playing fetch by himself by dropping a ball down a flight of stairs and bringing it back up to the top. Dr. Weisman says, for a dog, Drew is rather organized. He has his own toy box that he gets his things out of at the beginning of the day, but always brings them back and puts them away at the end of the day.

As for Brees, Dr. Lowery says, Im not the biggest football fan, but I have so much respect for Drew Brees. She says that Brees is about five-years-old and has a calm demeanor overall, but also is not afraid to act like a watchdog when she needs to. Dr. Lowery explains that when theyre home, She keeps all of the squirrels and chipmunks in line. When Brees is off-duty from her watchdog role, she enjoys being a greeter in the College of Veterinary Medicine. Students may find her in a hallway between classes always happy to be petted. Dr. Lowery says that students and staff love having Brees as a local mascot for the college.

Both of these dogs are involved in the colleges Pet Professor program. Animals in the program are often the pets of staff and faculty and provide a way for students to learn the foundations of conducting physical examinations and giving vaccinations to domestic pets as well as practicing ultrasounds and minor physical therapy techniques. Animals like Drew and Brees get a free examination while students get fun friends to play with and learn from, and who wouldnt want a teammate like Drew Brees!

Writer(s): Jonathan Martz, PVM Communications Intern | pvmnews@purdue.edu

Visit link:
It's Not Far-fetched to Find Drew Brees in the College of Veterinary Medicine - Purdue Veterinary News

Dr. Bell said keeping animals out of the smoke as much as possible is best case, but if they must be outside, pet owners should limit that time if possible.

By Josh Babcock, College of Veterinary Medicine

Until the smoke clears, Washington State University veterinarians say the best thing pet owners can do is keep their animals indoors.

According to an air quality alert issued by the Washington State Department of Ecology, widespread smoke and haze is expected to cause unhealthy air quality throughout the week.

I would take the same precautions for pets that you would take for you and your family, said Dr. Jessica Bell, a small animal veterinarian at WSUs College of Veterinary Medicine.

Dr. Bell said keeping animals out of the smoke as much as possible is best case, but if they must be outside, pet owners should limit that time if possible.

Heavy breathing is worse for animals in smoky conditions and any strenuous exercise should be avoided, she said.

Water bowls for animals can pick up pollutants and should be changed and monitored more often, especially those outdoors, Bell said. If their water is contaminated with whats in the air, they may hesitate to drink it next time.

Bell recommends monitoring elderly pets and pets with respiratory conditions when smoke is lingering.

Look for any discomfort, coughing, heavy breathing; sometimes conditions like these aggravate other problems, she said.

Bell said with so many particles in the air, now is the worst time for a dog to have its head out of the window of a vehicle, noting smoke irritates the face and eyes of animals.

If animals are showing signs of discomfort, it is best to consult your regular veterinarian.

Original post:
Veterinarians: Keep your pets out of the smoke - WSU News

As a second-generation veterinarian, Michael Blackwell, director of the Program for Pet Health Equity in the University of Tennessee, Knoxvilles College of Social Work, has witnessed the American publics behavior toward companion animals shift to treating them not just as pets but as family members.

With two-thirds of American households having nonhuman family members, the need for affordable veterinary care is more important than ever. With the 2008 recession, Blackwell saw firsthand a surge of families struggling to pay for services, specifically veterinary care, and he recognized the need to improve access to this care. The COVID-19 pandemic has significantly increased the number of families needing support.

We have tens of millions of individuals called pets embedded in communities across the country, and they dont have adequate access to care, Blackwell stated. That threatens not only the familys health but the communitys health and the nations well-being.

In 2017, Blackwell began leading an interdisciplinary team at UT composed of members from the College of Social Work, the Haslam College of Business, the College of Veterinary Medicine, and the Department of Public Health in the College of Education, Health, and Human Sciences to establish the program, which works to connect underserved individuals with veterinary service providers. In 2018 it received $2.8 million from Maddies Fund to research and develop AlignCare.

Were putting in place a system that will be in part a safety net but also a structured approach so we can more efficiently and effectively reach underserved families, Blackwell said.

As the programs director, Blackwell works with consultants and volunteers across the country to coordinate and reiterate its vision.

My vision is one day, any family that needs to see a doctor, whether its the human or the nonhuman member, will be able to see a doctor and get needed care, Blackwell said.

Blackwell integrates UT graduate students in business, public health, and social work into the program, providing eye-opening exposure to the differences between veterinary medicine and the health care industry and to the economic impacts of delivering health care.

In regard to his students, Blackwell said, Theyve come to appreciate how connected things are in this world. Students are regularly appreciating the humananimal bond, and the organizations providing family support services need to change their programs to see the holistic family.

Currently the program is operating in four citiesKnoxville; Asheville, North Carolina; Phoenix, Arizona; and Long Island, New York. These cities had interested partners who were on board and ready to start building this program within the communities.

Recently UT received $600,000 from the Dave & Cheryl Duffield Foundation to expand these services to Las Vegas and Reno, Nevada. Other U.S. communities will be added as funding permits.

Blackwell attributes much of the programs success to its past and current team members as well as the many partners, consultants, and volunteers who have stepped up.

The people who need assistance in our country are actually our neighborsand they are primarily the working poor, who, ironically, work in service industries, Blackwell said. As a nation we are fortunate we still have so many compassionate people in our midst.

Blackwell is the 2020 recipient of the Avanzino Leadership Award, recognizing his outstanding leadership and purposeful dedication to the humananimal bond.

To learn more about the Program for Pet Health Equity, visit pphe.utk.edu.

CONTACT

Heather Peters (heatherpeters@utk.edu)

Diane Carr Tolhurst (dcarr9@utk.edu)

Read more:
UT Receives Funding to Address Socioeconomic Barriers to Veterinary Care - Tennessee Today

As Americans begin pulling up their sleeves for an annual flu vaccine, researchers at the University of WisconsinMadison have provided new insights into an alternative vaccine approach that provides broader protection against seasonal influenza.

In a study published in Cell Reports Medicine today (Sept. 22), scientists describe a T-cell-based vaccine strategy that is effective against multiple strains of influenza virus. The experimental vaccine, administered through the nose, delivered long-lasting, multi-pronged protection in the lungs of mice by rallying T-cells, specialist white blood cells that quickly eliminate viral invaders through an immune response.

This three-dimensional, semi-transparent rendering of a whole influenza virus shows both the clover-like surface proteins on the outside of the virus, as well as the internal ribonucleoproteins on the inside. Existing influenza vaccines introduce proteins found on the surface of flu viruses to help induce immune protection. A new study by researchers at the UW School of Veterinary Medicine uses an internal nucleoprotein to stimulate the immune system in an effort to create a universal flu vaccine. Centers for Disease Control and Prevention

The research suggests a potential strategy for developing a universal flu vaccine, so you dont have to make a new vaccine every year, explains Marulasiddappa Suresh, a professor of immunology in the School of Veterinary Medicine who led the research. The findings also aid understanding of how to induce and maintain T-cell immunity in the respiratory tract, a knowledge gap that has constrained the development of immunization strategies. The researchers believe the same approach can be applied to several other respiratory pathogens, including the novel coronavirus that causes COVID-19.

We dont currently have any vaccine for humans on the market that can be given into the mucosa and stimulate T-cell immunity like this, says Suresh, a veterinarian with specialty training in studying T-cell responses to viral infections.

The strategy addresses the Achilles heel of flu vaccines, which is to achieve specific antibody responses to different circulating influenza strains annually, by harnessing T-cell immunity against multiple strains. In particular, the new approach calls into action tissue-resident memory T-cells, or TRM cells, which reside in the airways and lining of lung epithelial cells and combat invading pathogens. Like elite soldiers, TRM cells serve as front line defense against infection.

Marulasiddappa Suresh

We didnt previously know how to elicit these tissue-resident memory cells with a safe protein vaccine, but we now have a strategy to stimulate them in the lungs that will protect against influenza, explains Suresh. As soon as a cell gets infected, these memory cells will kill the infected cells and the infection will be stopped in its tracks before it goes further.

Flu vaccines work by arming the immune system with an enhanced ability to recognize and fight off the flu virus. Vaccines introduce proteins found on the surface of flu viruses, prompting the immune system to produce antibodies that are primed to react should the virus attack.

However, because strains must be predicted ahead of flu season in order to produce vaccines, the vaccine in any given year may not completely match the viral strains in circulation that season. Flu viruses frequently mutate and can differ across time and from region to region. In addition, protection is neither long-lasting nor universal.

Even though current vaccines that people get annually stimulate antibody responses, these antibodies dont cross-protect, notes Suresh. If there is a new flu strain not found in that years vaccine, the antibodies that we generated last year wont be able to protect. Thats when pandemics happen because there is a completely new strain for which we have no antibodies. That is a really big problem in the field.

The vaccine developed by Suresh and his team is directed against an internal protein of influenza specifically, nucleoprotein. This protein is conserved between flu strains, meaning its genetic sequences are similar across different strains of flu.

The vaccine also utilizes a special combination of ingredients, or adjuvants, that enhance an immune response, which the researchers developed to stimulate protective T-cells in the lungs. These adjuvants spur T-cells to form into different subtypes in the case of the experimental flu vaccine, memory helper T-cells and killer T-cells. By doing so, the vaccine leverages multiple modes of immunity.

Killer T-cells hunt down and kill influenza virus-infected cells. Helper T-cells assist killer T-cells and produce molecules to promote influenza control. In laboratory studies, the team found that both T-cell types were needed to protect against flu.

Researchers demonstrated in a mouse model of influenza that the vaccine provides long-lasting immunity at least 400 days after vaccination against multiple flu strains. They will next test the vaccine in ferrets and nonhuman primates, two animal models of influenza research more biologically similar to human infection and transmission.

The vaccines combination of adjuvants makes it adaptable to other pathogens and expands the toolbox for vaccine research, notes Suresh. He and his team have devised ways to program immunity to target multiple respiratory viruses. They are currently testing the same vaccine strategy against tuberculosis, which infects more than 10 million people globally each year, and human respiratory syncytial virus, or RSV, a major cause of lower respiratory tract infections during infancy and childhood.

The researchers believe the same vaccine technology can applied against SARS-CoV-2, the coronavirus that causes COVID-19. Based on the COVID-19 immunology, we know this vaccine strategy would most likely work, says Suresh.

The team is now developing an experimental vaccine against COVID-19 and conducting laboratory tests to measure its effectiveness in mice and hamsters, animal models for COVID-19. Initial unpublished studies in mice show that the vaccine stimulates strong T-cell immunity against COVID-19 in the lungs.

Along with its adaptability, this vaccine approach may harbor important safety benefits. Typically, long-lasting T-cell immune responses are stimulated by live vaccines. For instance, the measles, mumps and chickenpox vaccines administered worldwide are live, replicating vaccines essentially benign versions of the pathogenic organism. These live vaccines stimulate strong, almost lifelong immunity. However, they cant typically be given to pregnant or immunocompromised individuals due to health risks.

In the case of the UWMadison teams vaccine, because it is a protein vaccine and not a live vaccine, it should be safe for delivery to those who are pregnant or immunocompromised an advantage in delivering protection to a wider patient population. Suresh says that in recent years, vaccine development efforts have shifted away from live vaccines toward protein vaccines because an increasing number of people are living with compromised immune systems due to chemotherapy, radiation treatments or conditions such as HIV/AIDS.

Previously, we didnt know how to induce T-cell immunity in the lung without live viruses, says Suresh. If we cleverly use a combination adjuvant, which we have developed, you can induce T-cell immunity that should stay in the lungs and protect longer.

THIS WORK WAS supported by THE NATIONAL INSTITUTES FOR HEALTH (GRANT UO1124299).

The rest is here:
New vaccine strategy harnesses 'foot soldier' T-cells to provide protection against influenza - University of Wisconsin-Madison

Vaxart Inc (VXRT) is around the top of the Biotechnology industry according to InvestorsObserver. VXRT received an overall rating of 81, which means that it scores higher than 81 percent of all stocks. Vaxart Inc also achieved a score of 93 in the Biotechnology industry, putting it above 93 percent of Biotechnology stocks. Biotechnology is ranked 23 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 81 would rank higher than 81 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Vaxart Inc (VXRT) stock has risen 8.5% while the S&P 500 is lower by -1.67% as of 11:41 AM on Monday, Sep 21. VXRT is up $0.70 from the previous closing price of $8.22 on volume of 23,715,904 shares. Over the past year the S&P 500 has gained 9.10% while VXRT is up 1615.38%. VXRT lost -$0.60 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Vaxart Inc (VXRT) Stock.

Follow this link:
Is Vaxart Inc (VXRT) The Right Choice in Biotechnology? - InvestorsObserver

Chicago, United States: The global Agricultural Biotechnology For Transgenic Crops Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Agricultural Biotechnology For Transgenic Crops Market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Agricultural Biotechnology For Transgenic Crops Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Agricultural Biotechnology For Transgenic Crops Market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Agricultural Biotechnology For Transgenic Crops Market.

Leading players of the global Agricultural Biotechnology For Transgenic Crops Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Agricultural Biotechnology For Transgenic Crops Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Agricultural Biotechnology For Transgenic Crops Market. It also provides useful recommendations for new as well as established players of the global Agricultural Biotechnology For Transgenic Crops Market.

Request for Sample Copy of This Report @https://www.reporthive.com/request_sample/2437198

Major Players:Monsanto, DowDuPont, Syngenta, BayerCropScience, Rubicon, Vilmorin, CertisUSA, Evogene, KWSSAAT, ADAMAAgriculturalSolutions, PerformancePlants, GlobalBio-chemTechnology

Segmentation by Product:

Artificial Genetically Modified (GM)Natural Genetically Modified (GM)

Segmentation by Application:

CornSoybeanCottonOthers

For Customised Template PDF Report:https://www.reporthive.com/request_customization/2437198

Scope of the Report:The all-encompassing research weighs up on various aspects including but not limited to important industry definition, product applications, and product types. The pro-active approach towards analysis of investment feasibility, significant return on investment, supply chain management, import and export status, consumption volume and end-use offers more value to the overall statistics on the Agricultural Biotechnology For Transgenic Crops Market. All factors that help business owners identify the next leg for growth are presented through self-explanatory resources such as charts, tables, and graphic images.

The insight has been added in the report to provide realistic overview of the industry, consist of Agricultural Biotechnology For Transgenic Cropsmanufacturers data, i.e. shipment, price, revenue, gross profit, business distribution, etc., SWOT analysis, consumer preference, recent developments and trends, drivers and restrain factors, company profile, investment opportunity, demand gap analysis, forecast market size value/volume, services and product, Porters Five Models, socioeconomic factors, government regulation in Agricultural Biotechnology For Transgenic Crops industry. Market players can use the report to peep into the future of the global Agricultural Biotechnology For Transgenic Crops Market and bring important changes to their operating style and marketing tactics to achieve sustained growth.

Global Agricultural Biotechnology For Transgenic Crops Market: Competitive RivalryThe chapter on company profiles studies the various companies operating in the global Agricultural Biotechnology For Transgenic Crops Market. It evaluates the financial outlooks of these companies, their research and development statuses, and their expansion strategies for the coming years. Analysts have also provided a detailed list of the strategic initiatives taken by the Agricultural Biotechnology For Transgenic Crops Market participants in the past few years to remain ahead of the competition.

Main Aspects covered in the Report->>Overview of the Agricultural Biotechnology For Transgenic Crops market including production, consumption, status & forecast and market growth->>2016-2020 historical data and 2021-2026 market forecast->>Geographical analysis including major countries->>Overview the product type market including development->>Overview the end-user market including development->>Impact of Coronavirus on the Industry

Table of Contents

Report Overview:It includes major players of the global Agricultural Biotechnology For Transgenic Crops Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Agricultural Biotechnology For Transgenic Crops Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Agricultural Biotechnology For Transgenic Crops Market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Agricultural Biotechnology For Transgenic Crops Market by application, it gives a study on the consumption in the global Agricultural Biotechnology For Transgenic Crops Market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Agricultural Biotechnology For Transgenic Crops Market are profiled in this section. The analysts have provided information about their recent developments in the global Agricultural Biotechnology For Transgenic Crops Market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Agricultural Biotechnology For Transgenic Crops Market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Agricultural Biotechnology For Transgenic Crops Market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Agricultural Biotechnology For Transgenic Crops Market.

Key Findings: This section gives a quick look at important findings of the research study.

About Us:Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Contact Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

Read the original post:
Global Covid-19 impact on Agricultural Biotechnology For Transgenic Crops Market: Business Opportunities, Current Trends And Industry Analysis By 2020...

When I was looking for universities to apply for an undergraduate programme, I heard about Rabindranath Tagore University (RNTU) and decided to visit the campus. I was astonished to see all the facilities offered here. Since the educational institutions in and around Vidisha dont offer similar facilities, I moved to Bhopal to join RNTU for a programme in Biotechnology.

This subject is used in different fields, including agriculture, environment and medicine and is slowly gaining popularity in India, especially in relation to agriculture, organic crops as well as cross breeding.

Infrastructure

At RNTU, we have access to excellent labs and equipment required for research, such as an in-house DNA fingerprinting lab and this makes the educational experience really engrossing.

Also, the teachers are supportive and helpful in creating an interactive learning experience. Presentations and audiovisual lessons and use of technology make the classes compelling.

The exposure to practical learning, as well as extracurricular activities, has improved my management and leadership skills. It has enabled me come out of my shell and explore the world as well as my own capabilities. One of my best experiences was representing my university at a national level debate competition organised by the Amity University, Lucknow.

In addition to participating in competitions, I was also a part of the volunteering committee at Vishwa Rang, the Tagore International Literature and Arts Festival during which I met and interacted with many artists and writers.

I was also a member of the organising team for the annual college festival Rhythm. We decided each act, divided the responsibilities and mapped of various activities with deadlines proper execution.

Even during the lockdown, we are constantly getting various internship opportunities so that our future is not adversely affected by the pandemic.

Kanika Soni is a third-year undergraduate student of Biotechnology from the Rabindranath Tagore University, Bhopal

You have reached your limit for free articles this month.

To get full access, please subscribe.

Already have an account ? Sign in

Show Less Plan

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Move smoothly between articles as our pages load instantly.

Enjoy reading as many articles as you wish without any limitations.

A one-stop-shop for seeing the latest updates, and managing your preferences.

A select list of articles that match your interests and tastes.

We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

View original post here:
Biotech and beyond - The Hindu

One of the biggest winners among coronavirus stocks in 2020 has been Vir Biotechnology(NASDAQ:VIR). The company's shares have more than doubled in the span of one year, turning a $10,000 investment from last September into about $22,700 today. That substantially outperformed the S&P 500, which gained 15% over the same period.

But sometimes, the higher you climb, the harder you fall. Recent controversy surrounding the company's progress with its COVID-19 programs caused the stock to fall more than 40% from its peak in late August. Should investors expect this company and its stock to rebound? Let's take a look at whether buying Vir on the dip is a golden opportunity or whether the company's drug pipeline spells trouble for its future.

Image Source: Getty Images.

Vir has two antibody treatments and a small interfering RNA (siRNA) treatment against COVID-19 in its pipeline. siRNA therapeutic candidates are based on tiny double-stranded RNA sequences coded to destroy genetic material responsible for a virus' protein synthesis, rendering it unable to replicate. The RNA treatment is undergoing preclinical studies, the results from which are expected by the end of the year. Meanwhile, one of the company's antibodies, VIR-7832, will enter phase 2 clinical trials in the fourth quarter, while the other, VIR-7831, is in phase 2/3 clinical trials. The latter candidate could made available first under an early access program like an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in the early months of 2021, if trial results are positive.

Vir has partnered with GlaxoSmithKline(NYSE:GSK) to develop its COVID-19 programs. The company is responsible for research and development (R&D) costs while GlaxoSmithKline is handling commercialization costs. Under the agreement, 72.5% of costs and profits go to Vir while the remaining 27.5% are GlaxoSmithKline's.

Without a doubt, Vir's pipeline has potential. However, there are already coronavirus treatments on the market, including Gilead Sciences'(NASDAQ:GILD) antiviral, remdesivir, and the generic steroid, dexamethasone. What's more, large-cap biotechs such as Moderna(NASDAQ:MRNA) andPfizer(NYSE:PFE) are already far along in their efforts to develop coronavirus vaccines. In fact, a vaccine could be available as soon as October. While there are no guarantees that any one of the vaccine candidates in particular will prove effective against COVID-19, it is likely that by 2022, the need for coronavirus treatments will have significantly diminished as people around the world are (hopefully) inoculated.

The company's hepatitis B pipeline is facing similar problems. Even though its treatment candidates for the disease are well into phase 2 trials, the question of their commercial feasibility is a key concern. There are already a number of effective hepatitis B vaccines available worldwide, meaning that the need for a treatment is limited to those who don't get immunized (or those whose immunizations are ineffective) and subsequently contract the virus. While 257 million people are currently living with hepatitis B, many are in developing nations and may not have the purchasing power to afford a pricey treatment course.

If that wasn't enough, Arrowhead Pharmaceuticals (NASDAQ:ARWR) andJohnson & Johnson (NYSE:JNJ) are also on their way to developing a treatment for hepatitis B. Clinical data for their candidate has looked solid. Whatever comes out of Vir's pipeline would have to compete with both existing standard-of-care treatments such as Entecavir and Tenofovir and new ones from other biotechs. This would significantly affect the company's pricing power in the event of its drug's approval.

Vir only brought in $67 million in combined licensing plus collaboration revenues in the past quarter. But currently, it has about $552.4 million in cash and investments, is operating at a net loss of $31.2 million per quarter, and has a $4.05 billion market cap. So in terms of its ability to keep moving forward with research and development, Vir's financial position is fair.

However, I don't think its shaky pipeline can justify its stock price, even after a recent decline. The market opportunities for hepatitis B and COVID-19 treatment candidates are too unstable and full of heavyweight pharma competitors. Buying Vir Biotechnology now could be like catching a falling knife. Investors looking at coronavirus stocks may wish to consider other opportunities.

Link:
Should You Buy Vir Biotechnology Stock on the Dip? - Motley Fool

- Corporate restructuring to extend cash runway through mid-2022 and key milestones -

- UBX1325 to enter clinical development in patients with diabetic macular edema -

SAN FRANCISCO, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it has initiated a restructuring to align its resources on cellular senescence programs in ophthalmology and neurology while further extending operating capital. UNITY will advance UBX1325 to Phase 1 clinical development in patients with diabetic macular edema, and expects to dose the first patient in the second half of 2020, consistent with prior guidance.

UNITY has prioritized its portfolio and aligned resources to deliver on key development milestones and drive innovation:

UBX1325 targets Bcl-xL, a novel mechanism to eliminate senescent cells in age-related diseases of the eye. The UBX1325 Phase 1 study in diabetic macular edema is expected to begin before the end of the year. UBX1967 remains in the portfolio as a molecularly distinct backup to UBX1325.

UNITYs neurology programs will target core features of neurodegenerative diseases. These programs build upon UNITYs foundational cellular senescence research platform and will focus on senolytic therapies for neurological diseases as well as exploring novel mechanisms for cognitive benefit.

UNITYs research programs will explore therapeutic modalities beyond small molecule approaches to significantly expand the target space for modulating senescent cell biology implicated as drivers of diseases of aging.

Revised Financial Guidance

UNITY will reduce its workforce by approximately 30% to optimize capital allocation and align with key strategic priorities, resulting in an estimated 75 full-time employees by the end of the year. These steps to focus resources are expected to extend the cash runway through mid-2022, with current cash and cash equivalents projected to fund UNITY through key clinical data readouts for UBX1325 and IND-enabling studies for UBX1967.

Story continues

"UNITY is a pioneer in the development of therapeutics targeting senescent cells at the crux of many age-related diseases, and we will continue to build on this scientific foundation as we advance our pipeline," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "At UNITY, we have an extraordinary team that has contributed greatly to the advancement of this field, and we are deeply grateful for the contributions that all of our employees have made. Moving forward we will have a leaner and more agile team, which is well-resourced to advance our pipeline programs to key milestones."

Dr. Ghosh added: We are excited about advancing UNITYs lead ophthalmology program, UBX1325, into clinical studies in patients with diabetic macular edema, an indication with a well-defined development path and objective endpoints. In addition, I see significant opportunities emerging from programs in our preclinical pipeline targeting ophthalmologic and neurologic disease. I look forward to using my experience leading drug discovery and development programs in these areas to advance the development of a new class of high efficacy therapies.

About UNITYUNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available atwww.unitybiotechnology.comor follow us onTwitter.

Forward-Looking Statements

This press release contains forward-looking statements including statements related to UNITYs understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to extend healthspan, including for ophthalmologic and neurologic disease, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for diabetic macular edema and other ophthalmological diseases, the expected timing of initial results of the Phase 1 study of UBX1325 in diabetic macular edema, the expected size of UNITYs workforce following the restructuring, the impact of the workforce reduction on UNITYs business, and UNITYs expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITYs most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, filed with the Securities and Exchange Commission on July 31, 2020, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.

Read the original here:
UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology - Yahoo Finance

Latest Research Report: Piceatannol industry

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

Global Piceatannol Market documents a detailed study of different aspects of the Global Market. It shows the steady growth in market in spite of the fluctuations and changing market trends. The report is based on certain important parameters.

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/148723

Piceatannol Market competition by top manufacturers as follow:Shaanxi Fuheng (FH) BiotechnologyXian Lyphar BiotechXian Finesky TechnologicalXa Bc-BiotechXian Huisun Bio-TechRiotto BotanicalXian Biof Bio-Technology

The risingtechnology in Piceatannolmarketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail. It includes a meticulous analysis of market trends, market shares and revenue growth patterns and the volume and value of the market. It is also based on a meticulously structured methodology. These methods help to analyze markets on the basis of thorough research and analysis.

The Type Coverage in the Market are: Industrial GradePharmaceutical Grade

Market Segment by Applications, covers:DrugsCosmeticsOthers

The research report summarizes companies from different industries. This Piceatannol Market report has been combined with a variety of market segments such as applications, end users and sales. Focus on existing market analysis and future innovation to provide better insight into your business. This study includes sophisticated technology for the market and diverse perspectives of various industry professionals.

Piceatannol is the arena of accounting worried with the summary, analysis and reporting of financial dealings pertaining to a business. This includes the training of financial statements available for public ingesting. The service involves brief, studying, checking and reporting of the financial contacts to tax collection activities and objects. It also involves checking and making financial declarations, scheming accounting systems, emerging finances and accounting advisory.

To get this report at a profitable rate.: https://reportsinsights.com/discount/148723

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Report Highlights: Detailed overview of parent market Changing market dynamics in the industry In-depth market segmentation Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape Strategies of key players and products offered Potential and niche segments, geographical regions exhibiting promising growth A neutral perspective on market performance Must-have information for market players to sustain and enhance their market footprint

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Piceatannol-Market-148723

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Originally posted here:
Piceatannol Market Incredible Possibilities, Growth Analysis and Forecast To 2025 | Shaanxi Fuheng (FH) Biotechnology, Xian Lyphar Biotech, Xian...

Plant Biotechnology Equipment Market Data and Acquisition Research Study with Trends and Opportunities 2019-2025The study of Plant Biotechnology Equipment market is a compilation of the market of Plant Biotechnology Equipment broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Plant Biotechnology Equipment industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Plant Biotechnology Equipment industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

Request a sample of Plant Biotechnology Equipment Market report @ https://hongchunresearch.com/request-a-sample/60575

The following manufacturers are covered:Keygene(Netherlands)Heinz Walz GmbH (Germany)LemnaTec(Germany)Photon Systems Instruments(Czech Republic)Qubit Systems (Canada)Thermo Fisher Scientific (US)Tecan Group (Switzerland)LabRepCo (US)Geneq (Canada)Illumina (US)LGC Limited (UK)Evogene (Israel)

Access this report Plant Biotechnology Equipment Market @ https://hongchunresearch.com/report/worldwide-plant-biotechnology-equipment-market-2019-60575

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeSensors ModulesImaging DevicesAutomated SystemDronesLED LightingPortable Devices

Segment by ApplicationPlant ResearchBreedingProduct DevelopmentQuality AssessmentOthers

For a global outreach, the Plant Biotechnology Equipment study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses:Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitionsRevenue, cost price, capacity & utilizations, import/export rates and market shareForecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

To Check Discount of Plant Biotechnology Equipment Market @ https://hongchunresearch.com/check-discount/60575

Major Point of TOC:

Chapter One: Plant Biotechnology Equipment Market Overview

Chapter Two: Global Plant Biotechnology Equipment Market Competition by Manufacturers

Chapter Three: Global Plant Biotechnology Equipment Production Market Share by Regions

Chapter Four: Global Plant Biotechnology Equipment Consumption by Regions

Chapter Five: Global Plant Biotechnology Equipment Production, Revenue, Price Trend by Type

Chapter Six: Global Plant Biotechnology Equipment Market Analysis by Applications

Chapter Seven: Company Profiles and Key Figures in Plant Biotechnology Equipment Business

Chapter Eight: Plant Biotechnology Equipment Manufacturing Cost Analysis

Chapter Nine: Marketing Channel, Distributors and Customers

Chapter Ten: Market Dynamics

Chapter Eleven: Global Plant Biotechnology Equipment Market Forecast

Chapter Twelve: Research Findings and Conclusion

Chapter Thirteen: Methodology and Data Source 13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Author List13.4 Disclaimer

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

Link:
Impact Of Covid-19 on Plant Biotechnology Equipment Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - The Daily...

Executive summary:

The latest report on Biotechnology Separation Systems market strives to provide a conclusive overview of the current and future market scenario with respect to the key growth catalysts, challenges, and opportunities across the various geographies.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/6449

The Biotechnology Separation Systems market is projected to expand with a CAGR of XX% during the forecast period 2020-2025.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/6449

In addition to region wise-assessment, the study also draws attention towards the competitive landscape by profiling the top contenders in the industry. A complete analysis of the various market segmentation is underlined in the report. Additionally, a detailed visualization of the global Covid-19 impact on the growth matrix of this business space is provided.

Market synopsis:

Regional outlook:

Product terrain outline:

Application spectrum overview:

Competitive landscape review:

Additional information from the Biotechnology Separation Systems market report:

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

Market segmentation

The Biotechnology Separation Systems market is split by Type and by Application. For the period 2020-2025, the growth among segments provides accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Research Objective:

Why to Select This Report:

The research process begins with internal and external sources to obtain qualitative and quantitative information related to the Biotechnology Separation Systems market. It also provides an overview and forecast for the Biotechnology Separation Systems market based on all the segmentation provided for the global region. The predictions highlighted in the Biotechnology Separation Systems market share report have been derived using verified research procedures and assumptions. By doing so, the research report serves as a repository of analysis and information for every component of the Biotechnology Separation Systems market.

Request Customization on This Report @ https://www.theresearchprocess.com/request-for-customization/6449

Read the rest here:
Biotechnology Separation Systems Market Analysis, Revenue, Share, Growth Rate & Forecast To 2025 - The Research Process

REHOVOT, Israel and SILVER SPRING, Maryland, Sept. 21, 2020 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) and United Therapeutics Corporation (NASDAQ: UTHR) today announced an expansion of their collaboration with the exercise by United Therapeutics of its option to cover a second lifesaving organ, human kidneys. United Therapeutics paid CollPlant $3 million for the option exercise.

The collaboration agreement combines CollPlant's proprietary recombinant human collagen (rhCollagen) and BioInk technology with the regenerative medicine and organ manufacturing capabilities of United Therapeutics.

The option exercise grants United Therapeutics through its wholly owned organ manufacturing and transplantation-focused subsidiary, Lung Biotechnology PBC, an exclusive license to CollPlant's technology for the production and use of rhCollagen-based BioInk for 3D bioprinting of human kidneys. This expanded collaboration is aimed at helping reduce global organ shortages and thereby potentially saving lives of millions of patients on kidney waiting lists.

"Organ shortages are an unmet global health need and by partnering with United Therapeutics for the past couple of years, we have made significant progress with this pivotal organ manufacturing initiative," stated Yehiel Tal, the Chief Executive Officer of CollPlant. "United Therapeutics is pioneering the emerging organ manufacturing field, and we are honored to be part of this effort via this partnership. This option exercise demonstrates another important validation of our rhCollagen platform technology, performing as an optimal building block for regenerative medicine. We remain committed to exploring new innovative applications in the fields of medical aesthetics and 3D bioprinting of tissues and organs."

"We are excited to expand our collaboration with CollPlant's extraordinary technology to transform the tobacco plant one that is so associated with devastating diseases into a collagen-expressing plant that will be essential to the production of an unlimited number of transplantable organs," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. "Our collagen-expressing plants are already flourishing in Texas where we enjoy three growing seasons."

The collaboration agreement itself, which was signed in October 2018, granted United Therapeutics an exclusive license to CollPlant's technology for the production and use of rhCollagen-based BioInk for 3D bioprinted lung transplants. CollPlant will manufacture and supply BioInk for a few years to meet development process demand and will provide technical support to United Therapeutics as it establishes a U.S. facility for the manufacture of CollPlant's rhCollagen and BioInk.

Under financial terms of the original collaboration agreement, CollPlant received an upfront payment of $5 million and will receive milestone payments of up to $15 million based on the achievement of certain operational and regulatory milestones related to the development of manufactured lungs. The agreement also provides United Therapeutics with an option to extend the license to two remaining additional life-saving organs with option exercise payments of up to $6 million. As a result of the option exercise for human kidneys these options have been extended for an additional one year through November 9, 2021. The agreement also provides additional developmental milestone payments of up to $15 million if United Therapeutics elects to develop manufactured organs other than lungs using CollPlant's technology. CollPlant will also be entitled to royalties on sales of commercialized products covered by patents licensed from CollPlant.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. CollPlant's products are based on its rhCollagen (recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering technology.

CollPlant's products address indications for the diverse fields of tissue repair, aesthetics and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.

CollPlant's flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs. In October 2018, CollPlant entered into a licensing agreement with United Therapeutics, whereby United Therapeutics is using CollPlant's BioInks in the manufacture of 3D bioprinted lungs for transplant in humans.

In January 2020, CollPlant entered into a Joint Development Agreement with 3D Systems Corporation, or 3D Systems, pursuant to which CollPlant and 3D Systems jointly develop tissue and scaffold bioprinting processes for third party collaborators. CollPlant's industry collaboration also includes the Advanced Regenerative Manufacturing Institute, or ARMI.

For more information, visit http://www.collplant.com.

About United Therapeutics Corporation

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership. We also believe that our determination to be responsible citizens having a positive impact on patients, the environment, and society will sustain our success in the long term.

Through our wholly owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

Safe Harbor for Forward-Looking Statements

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's and United Therapeutics' objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant and United Therapeutics each intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's and United Therapeutics' actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the CollPlant's history of significant losses and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; CollPlant's and United Therapeutics' expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen-based BioInk; the CollPlant's and United Therapeutics' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen-based BioInk, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the CollPlant's rhCollagen-based BioInk and United Therapeutics' manufactured organs; CollPlant's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third-party distributors and resellers; CollPlant's and United Therapeutics' ability to establish and maintain strategic partnerships and other corporate collaborations; CollPlant's and United Therapeutics' reliance on third parties to conduct some aspects of its product manufacturing; the scope of protection CollPlant and United Therapeutics are able to establish and maintain for intellectual property rights and the companies' ability to operate their business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the companies operate; projected capital expenditures and liquidity; changes in the companies' strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant and United Therapeutics is contained under the heading "Risk Factors" included in CollPlant's and United Therapeutics' most recent annual report on Form 20-F and Form 10-K, respectively, filed with the SEC, and in other filings that CollPlant and United Therapeutics have made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's and United Therapeutics' current views with respect to future events, and neither company undertakes, and each company specifically disclaims, any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts at CollPlant:Eran RotemDeputy CEO & Chief Financial OfficerTel: + 972-73-2325600/612Email: Eran@collplant.com

Sophia Ononye-Onyia, PhD MPH MBAFounder & CEO, The Sophia Consulting FirmTel: +1-347-851-8641E-mail: sophia@sophiaconsultingfirm.com

Contact at United Therapeutics:Dewey SteadmanHead of Investor RelationsTel: + 1 (202) 919-4097Email: ir@unither.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/collplant-and-united-therapeutics-announce-exercise-of-option-that-will-expand-their-collaboration-to-include-3d-bioprinting-of-human-kidneys-for-transplant-301134527.html

SOURCE CollPlant; United Therapeutics Corporation

Company Codes: NASDAQ-NMS:CLGN, ISIN:IL0004960188, RICS:CLPT.TA, RICS:CQPTY, NASDAQ-NMS:UTHR

The rest is here:
CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for...

PDS Biotechnology Corporation [NASDAQ: PDSB] price surged by 10.98 percent to reach at $0.28. The company report on September 8, 2020 that PDS Biotechnology to Participate in Upcoming Healthcare Investor Conferences.

PDS Biotechnology Corporation (PDS Biotech or the Company) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced that Frank Bedu-Addo, CEO of PDS Biotech, will present virtually at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 16th and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23rd.

H.C. Wainwright & Co. 22nd Annual Global Investment Conference:Date: Wednesday, September 16th, 2020Location: https://wsw.com/webcast/hcw7/pdsb/1599649Time: 2:30 PM ET.

A sum of 1192998 shares traded at recent session while its average daily volume was at 1.90M shares. PDS Biotechnology Corporation shares reached a high of $2.85 and dropped to a low of $2.45 until finishing in the latest session at $2.83.

The average equity rating for PDSB stock is currently 2.20, trading closer to a bullish pattern in the stock market.

Alliance Global Partners have made an estimate for PDS Biotechnology Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 27, 2020. While these analysts kept the previous recommendation, Noble Capital Markets raised their target price to Outperform. The new note on the price target was released on March 09, 2020, representing the official price target for PDS Biotechnology Corporation stock. Previously, the target price had yet another raise to $10, while Chardan Capital Markets analysts kept a Buy rating on PDSB stock.

The Average True Range (ATR) for PDS Biotechnology Corporation is set at 0.22 The Price to Book ratio for the last quarter was 2.55, with the Price to Cash per share for the same quarter was set at 0.88.

PDS Biotechnology Corporation [PDSB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 31.02. With this latest performance, PDSB shares dropped by -4.07% in over the last four-week period, additionally plugging by 322.39% over the last 6 months not to mention a drop of -50.44% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PDSB stock in for the last two-week period is set at 55.48, with the RSI for the last a single of trading hit 67.29, and the three-weeks RSI is set at 53.92 for PDS Biotechnology Corporation [PDSB]. The present Moving Average for the last 50 days of trading for this stock 2.98, while it was recorded at 2.55 for the last single week of trading, and 1.93 for the last 200 days.

Return on Total Capital for PDSB is now -74.68, given the latest momentum, and Return on Invested Capital for the company is -33.70. Return on Equity for this stock declined to -33.70, with Return on Assets sitting at -27.60.

Reflecting on the efficiency of the workforce at the company, PDS Biotechnology Corporation [PDSB] managed to generate an average of -$349,930 per employee.PDS Biotechnology Corporations liquidity data is similarly interesting compelling, with a Quick Ratio of 7.70 and a Current Ratio set at 7.70.

With the latest financial reports released by the company, PDS Biotechnology Corporation posted -1.1/share EPS, while the average EPS was predicted by analysts to be reported at -0.82/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -34.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PDSB.

There are presently around $5 million, or 8.00% of PDSB stock, in the hands of institutional investors. The top three institutional holders of PDSB stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 622,672, which is approximately 101.108% of the companys market cap and around 35.92% of the total institutional ownership; FEDERATED HERMES, INC., holding 384,000 shares of the stock with an approximate value of $1.09 million in PDSB stocks shares; and FIRST MANHATTAN CO, currently with $0.42 million in PDSB stock with ownership of nearly 0% of the companys market capitalization.

Positions in PDS Biotechnology Corporation stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 10 institutional holders increased their position in PDS Biotechnology Corporation [NASDAQ:PDSB] by around 462,139 shares. Additionally, 12 investors decreased positions by around 392,147 shares, while 14 investors held positions by with 848,804 shares. The mentioned changes placed institutional holdings at 1,703,090 shares, according to the latest SEC report filing. PDSB stock had 6 new institutional investments in for a total of 72,701 shares, while 9 institutional investors sold positions of 372,040 shares during the same period.

Follow this link:
PDS Biotechnology Corporation [PDSB] gain 6.79% so far this year. What now? - The DBT News

The 94 rating InvestorsObserver gives to Aquestive Therapeutics Inc (AQST) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 100 percent of stocks in the Biotechnology industry, AQSTs 94 overall rating means the stock scores better than 94 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 94 would rank higher than 94 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Aquestive Therapeutics Inc (AQST) stock is trading at $8.78 as of 3:10 PM on Monday, Sep 21, a decline of -$0.27, or -2.98% from the previous closing price of $9.05. The stock has traded between $8.52 and $9.09 so far today. Volume today is 945,661 compared to average volume of 1,159,181.

Click Here to get the full Stock Score Report on Aquestive Therapeutics Inc (AQST) Stock.

View original post here:
Is Aquestive Therapeutics Inc (AQST) the Top Pick in the Biotechnology Industry? - InvestorsObserver

MacroGenics Inc (MGNX) is near the top in its industry group according to InvestorsObserver. MGNX gets an overall rating of 64. That means it scores higher than 64 percent of stocks. MacroGenics Inc gets a 75 rank in the Biotechnology industry. Biotechnology is number 23 out of 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

MacroGenics Inc (MGNX) stock is trading at $27.70 as of 1:10 PM on Monday, Sep 21, a decline of -$3.90, or -12.34% from the previous closing price of $31.60. The stock has traded between $27.45 and $30.56 so far today. Volume today is 456,042 compared to average volume of 558,970.

Click Here to get the full Stock Score Report on MacroGenics Inc (MGNX) Stock.

Originally posted here:
Is MacroGenics Inc (MGNX) a Winner in the Biotechnology Industry? - InvestorsObserver

Time seemed to pause for Willie Hawes.

How do you measure time?

By minutes?By moments? By memories?

If you go by years, Willie Hawes has us all beat.

Somewhere in themid-1980s, The Augusta Chronicle's reporters discovered Hawes, a retired farmer living near Appling.

He was a quiet man, beloved by a large family that called him "Papa," unremarkable perhaps, except that he was then 113 years old and would live to be 120.

He didn't have a birth certificate. Georgia didn't begin to keep such records until 1919 when he was 47. But he did appear in a church census in his native Lincoln County, which recorded his arrival as Jan. 15, 1872.

Think about that.

In January 1872, Ulysses S. Grant had not finished his first term as president. The flag of the United States only had 37 stars and George Armstrong Custer still had his hair.

After discovery of Hawes' singular longevity, a series of reporters would stop by each January for an update on his health, a wrapup of his birthday celebration and any possible insights into how one lives more than a century.

Despite growing deafness and failing sight, Hawes was kind and gracious.He preached the virtues of common sense and "eating the right foods."

His family would laugh and point out his appetite was legendary.

He liked to eat corn, spaghetti, fried chicken, turnip greens, pecan pie and a number of "stick-to-your-ribs" menu items,they'd say.

At one birthday banquet, he finished off potato salad, chitterlings, cabbage and cornbread,and then had yellow cake with white icing for dessert. They didn't bother with candles on his cakes, either, because by thetime you got all 100-plus lighted, some had melted down.

Yes, he ate well much of his life, but he also worked hard,usually with a mule and a plow. He did this a long time, explaining, "that way you know what you're eating."

He farmed in Lincoln County until 1924 when a flood prompted amove to Columbia County,where he continued to farm into his 80s.

He was always a robust man, who decided to demonstrate his agility at age 100 by leaping onto the hood of a grandson's car. His children and grandchildren loved to hear him tell stories, but also knew him as a strict disciplinarian who "only had to whip you once."

By the time Hawes reached 118, NBC's well-known weatherman Willard Scott of the Today Show began to salute his birthdays in national broadcasts.

When Hawes turned 120 in 1992, the newspaper sought out a doctor, who called him "an extraordinary physical specimen," and attributed his long life to family genetics, a good heart, low cholesterol, hard work and a healthy diet.

That was the last reporter visit.

Willie Hawes died April 26, 1992. He was 120 years, 3 months and 11 days old.He was buried in the Second Mount Carmel Baptist Church cemetery and his funeralwas no doubt well attended.

Survivors included three daughters, one son, an adopted son, five stepsons, three stepdaughters, a brother, 46 grandchildren, 113 great-grandchildren and 84 great-great grandchildren.

Visit link:
The Way We Were: Applings Willie Hawes, a legend of longevity - The Augusta Chronicle